Monogram and Dana-Farber Cancer Institute start HERmark study
This article was originally published in Clinica
Executive Summary
Monogram Biosciences has started a study of its HERmark assay in metastatic breast cancer, in collaboration with the Dana-Farber Cancer Institute in Boston. The test quantifies expression of the HER2 gene, identifying patients who respond to HER2-targeting therapies like Roche's Herceptin (trastuzumab). The trial will analyse 600 tissue samples – around half of which were from patients eligible for Herceptin treatment – and compare them with results of immunohistochemistry and/or fluorescence in situ hybridisation testing, the current standards for measuring HER2 levels. These are only semi-quantitative, South San Francisco, California-based Monogram says. The trial will also measure response to Herceptin treatment, as previous studies suggest that HERmark can identify subsets of patients likely to respond to the drug.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.